Great article! ... love this bit
In the months leading up to the trial results, the A$16.8 million capped play has been busy securing distribution partners and readying its sales channels in anticipation of the final results.
It has slowly but surely been honing in on its target market across multiple continents, having already signed distribution partners across Germany, Switzerland, Austria, Greece, Australia, India and the Middle East since late 2016.
And it’s a big market we are talking about here.
Ann: US Clinical Trial Results Published, page-36
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
